BN
BNIGF.US Beroni Group Limited
- Market cap
- USD 218K
- P/E
- -
- P/B
- 0.05x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2023.
Is BNIGF.US undervalued?
Graham numberThe Graham number of Beroni Group Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beroni Group Limited fundamental analysis
No fundamental analysis for Beroni Group Limited yet.
Beroni Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beroni Group Limited
Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics, and viral diagnostic kits in China. It operates through four segments: Cell Therapies; Developing New Anti-Cancer Drugs; E-commerce Platform for Pharmaceutical and Healthcare Products; and Detection & Diagnosis of Infectious Diseases. The company offers NicoBloc, a smokin…
Full company profileBeroni Group Limited financial statements
Beroni Group Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.10M | 4.36M | 2.29M | 2.16M | 1.70M | 1.79M | 2.20M | 639K | 469K |
| Gross Profit | 752K | 2.82M | 1.79M | 1.66M | 1.26M | 713K | 1.80M | 328K | -66.8K |
| Operating Income | -315K | 635K | -624K | -2.63M | -5.13M | -5.28M | -3.19M | -8.16M | -5.63M |
| EBITDA | - | - | -558K | -2.60M | -7.74M | -10.0M | -2.80M | -8.19M | -9.13M |
| Net Income | -159K | 476K | -725K | -2.43M | -7.77M | -9.98M | -2.66M | -8.07M | -9.23M |
| EPS | - | - | -0.01 | -0.03 | -0.11 | -0.13 | -0.03 | -0.11 | -0.46 |
| Balance Sheet | |||||||||
| Total Assets | 2.43M | 4.54M | 11.3M | 18.6M | 14.8M | 11.6M | 11.9M | 10.4M | 10.1M |
| Total Liabilities | 751K | 2.39M | 484K | 389K | 1.70M | 1.51M | 3.60M | 2.80M | 10.1M |
| Shareholders' Equity | 1.68M | 2.15M | 10.8M | 18.2M | 13.1M | 10.1M | 8.31M | 7.58M | -214.00 |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 3.01M | 4.77M | 5.74M | 2.58M | 4.04M |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.66M | 1.46M | -1.80M | -3.54M | -3.52M | -1.35M | -1.35M | - | - |
| Capital Expenditure | 10.6K | 137K | 24.8K | 250K | 9.35K | 6.18K | 5.65K | 867K | 5.05K |
| Free Cash Flow | - | - | -1.82M | -5.13M | -3.53M | -1.41M | -2.02M | -2.82M | -2.72M |
| Ratios | |||||||||
| ROE | -9.5% | 22.1% | -6.7% | -13.3% | -59.2% | -99.2% | -32.1% | -106.4% | - |
| ROA | -6.5% | 10.5% | -6.4% | -13.0% | -52.4% | -86.2% | -22.4% | -77.7% | -91.6% |
| Net Profit Margin | -14.4% | 10.9% | -31.6% | -112.2% | -457.6% | -556.4% | -121.2% | -1,263.0% | -1,968.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Beroni Group Limited dividends
Beroni Group Limited has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Oct 30, 2023.
Who owns Beroni Group Limited
- Insiders 86.11%
- Institutions 0.00%
- Public & others 13.89%
- Shares outstanding 34.0M
- Free float 11.5M
Beroni Group Limited company profile
- Company name
- Beroni Group Limited
- Ticker
- BNIGF.US
- ISIN
- AU000000BTG8
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Industrial Conglomerates
- Fiscal year end
- December
- Address
- Gateway, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9159 1827
- Website
- beronigroup.com
About Beroni Group Limited
Beroni Group Limited, together with its subsidiaries, develops and sells smoking control products, air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics, and viral diagnostic kits in China. It operates through four segments: Cell Therapies; Developing New Anti-Cancer Drugs; E-commerce Platform for Pharmaceutical and Healthcare Products; and Detection & Diagnosis of Infectious Diseases. The company offers NicoBloc, a smoking cessation/harm reduction product; SARS-CoV-2 IgG/IgM antibody detection kit; COVID-19 Antigen Rapid Test Kit; Bei Feiqing Tablet Candy, Bei Jingli Tablet Candy, and Beilemei freeze-dried powder; and cosmetic products, such as V show rejuvenation liquid, hyaluronic acid moisturizing silk mask, and avocado poly-peptide intensive treatment silk mask. It also provides CII-ArboViroPlex rRT-PCR assay that detects zika, dengue, chikungunya, and west nile viruses; stem cell cosmetics products comprising AGG Skin-Smoothing and Anti-Wrinkle Facial Mask, AGG Skin-Smoothing and Anti-Wrinkle Sample Pack, ODd Skin Repair Essence, AGG Skin-Smoothing and Anti-Wrinkle Essence, and ODd Beroni Beauty Facial Mask; and cardiology, hepatology, and oncology and immunotherapy solutions. In addition, the company offers cell therapies for cancer treatment; research on the treatment of cancer, as well as development of targeted therapies, immunotherapies, cancer vaccines, chemotherapy, radiation therapy, and surgery; and provides e-commerce platform for pharmaceutical and healthcare products. Further, it provides fogibloc air purifier and olansi water filter products. Beroni Group Limited was founded in 2014 and is headquartered in Sydney, Australia.
Beroni Group Limited management
4- Mr. Boqing ZhangFounder, Executive Chairman, MD & CEO · born 1970
- Mr. Hai HuangGroup COO, Founder & Executive Director · born 1968
- Mr. Yap Ting WongCFO & Executive Director · born 1962
- Mr. Chen Chik Ong ACIS, ACSA, B.Com., FCIS, GradDipAppFin, M.B.A.Non-Executive Director & Company Secretary · born 1978